Molecular Imaging Directed, 3D Ultrasound-guided, Biopsy System

分子成像引导、3D 超声引导、活检系统

• 批准号: 8791308
• 负责人: BAOWEI FEI
• 金额: $ 37.62万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-01-01 至 2016-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8791308
• 关键词: Address; Affect; Age; Animal Experiments; Animals; Appearance; Benign; Biopsy; Brachytherapy; Cancer Detection; Carcinoma; Clinical Trials; Cold Therapy; Collaborations; Computer software; Core Biopsy; Databases; Devices; Diagnosis; Dimensions; Disease; Disease Management; Face; Human; Image; Image Guided Biopsy; Imaging Techniques; Imaging technology; Joints; Kidney; Liver; Location; Lung; Malignant Neoplasms; Malignant neoplasm of prostate; Maps; Measures; Mechanics; Medical; Methods; Modeling; Molecular; Needles; Ontario; Organ; PUVA Photochemotherapy; Patients; Phase II Clinical Trials; Physicians; Poaceae; Positioning Attribute; Positron-Emission Tomography; Procedures; Prostate; Recruitment Activity; Research; Research Institute; Risk; Sampling Errors; Shapes; Speed; System; Techniques; Technology; Testing; Thermal Ablation Therapy; Three-Dimensional Image; Time; Tissues; Tracer; Transrectal Ultrasound; Ultrasonography; United States National Institutes of Health; Universities; base; blind; cancer therapy; cost; image guided; image registration; improved; innovation; man; men; minimally invasive; molecular imaging; multimodality; novel; programs; prostate biopsy; radiofrequency; spectroscopic imaging; three-dimensional modeling; tumor; two-dimensional; vector; young man

DESCRIPTION (provided by applicant): Prostate cancer affects 1 in 6 men in the USA. Every man over the age of 45 is at risk for prostate cancer. Systematic transrectal ultrasound (TRUS)-guided biopsy is the standard method for a definitive diagnosis of prostate cancer. More than 1.2 million prostate biopsies are performed annually and the medical cost is more than two billion dollars each year. However, this technique has a significant sampling error and is characterized by low sensitivity (39-52%). This "blind" biopsy approach can miss 30% of prostate cancers. As a negative biopsy does not preclude the possibility of a missed cancer, both the physicians and patients face challenges in making treatment decisions. Due to the increasing number of younger men with potentially early and curable prostate cancer, this problem must be addressed in order to improve cancer detection rate. At our NIH/NCI-supported Emory Molecular and Translational Imaging Center, positron emission tomography (PET) with a new molecular imaging tracer FACBC has shown very promising results for prostate cancer detection in human patients. We hypothesize that FACBC PET molecular images can be incorporated into ultrasound-guided biopsy for improved cancer detection. The proposed research is to develop a molecular image-directed, 3D ultrasound-guided system for targeted biopsy of the prostate. Specific Aim 1: To modify a real-time, mechanically assisted, 3D ultrasound-guided device. Compared to conventional 2D image guidance, 3D images of the prostate will be used to guide the biopsy. Specific Aim 2: To develop fast deformable and statistical appearance model based segmentation methods for 3D ultrasound images of the prostate. Statistical shape models will be developed from our database and will be used to guide automatic segmentation of the prostate. Specific Aim 3: To combine FACBC molecular images with 3D ultrasound for targeted biopsy. New deformable image registration methods based joint saliency map and fuzzy point correspondence will be developed in order to solve major limitations of mutual information based image registration. Specific Aim 4: To test the accuracy of the integrated biopsy system in phantoms and animals. The complete biopsy system will also be tested in a small number of human patients. Our FACBC patient studies are supported by the NIH-sponsored imaging center program (P50CA128301) and by the Phase II Clinical Trial (NCT00562315). The mechanically assisted device has received the FDA 510K approval. The proposed study will promote the academic-industrial collaboration (Emory University, Robarts Research Institute of the University of Western Ontario, and Eigen Inc., Grass Valley, CA). If completely developed, the multimodality molecular image-guided system will be able to be used not only for biopsy but also for brachytherapy, radiofrequency thermal ablation, cryotherapy, and photodynamic therapy.

描述（由申请人提供）：美国六分之一的男性患有前列腺癌。每个 45 岁以上的男性都有患前列腺癌的风险。系统性经直肠超声 (TRUS) 引导下的活检是前列腺癌明确诊断的标准方法。每年进行超过120万例前列腺活检，每年的医疗费用超过20亿美元。然而，该技术存在较大的采样误差，并且具有灵敏度低（39-52%）的特点。这种“盲目”活检方法可能会漏掉 30% 的前列腺癌。由于活检呈阴性并不能排除漏诊癌症的可能性，因此医生和患者在做出治疗决策时都面临挑战。由于患有潜在早期和可治愈前列腺癌的年轻男性数量不断增加，必须解决这个问题，以提高癌症检出率。在我们 NIH/NCI 支持的埃默里分子和转化成像中心，采用新型分子成像示踪剂 FACBC 的正电子发射断层扫描 (PET) 在人类患者前列腺癌检测方面显示出非常有希望的结果。我们假设 FACBC PET 分子图像可以纳入超声引导活检中，以改善癌症检测。拟议的研究是开发一种分子图像引导的 3D 超声引导系统，用于前列腺的靶向活检。具体目标 1：修改实时、机械辅助、3D 超声引导设备。与传统的 2D 图像引导相比，前列腺的 3D 图像将用于引导活检。具体目标 2：开发基于快速可变形和统计外观模型的前列腺 3D 超声图像分割方法。统计形状模型将从我们的数据库中开发出来，并将用于指导前列腺的自动分割。具体目标3：将FACBC分子图像与3D超声相结合进行靶向活检。将开发基于联合显着图和模糊点对应的新的变形图像配准方法，以解决基于互信息的图像配准的主要局限性。具体目标 4：测试体模和动物中集成活检系统的准确性。完整的活检系统也将在少数人类患者中进行测试。我们的 FACBC 患者研究得到 NIH 资助的影像中心计划 (P50CA128301) 和 II 期临床试验 (NCT00562315) 的支持。该机械辅助装置已获得 FDA 510K 批准。拟议的研究将促进学术与工业合作（埃默里大学、西安大略大学罗巴茨研究所和加利福尼亚州草谷的 Eigen Inc.）。如果开发完成，多模态分子图像引导系统不仅可以用于活检，还可以用于近距离放射治疗、射频热消融、冷冻治疗和光动力治疗。